T 1913/21 has received attention for nicely illustrating the difference between process claims and second non-medical use claims —a category of claims shaped by landmark Enlarged Board decisions G 2…
The withdrawal of the European Commission’s Standard Essential Patents (SEPs) Regulation proposal earlier this year has left a significant void in EU intellectual property policy. This decision was…
The Federal Court’s decision in The NOCO Company v Brown and Watson International Pty Ltd [2025] FCA 887 has provided a welcome update on the relevant date for assessing the best method knowledge…
Traditionally, patents are territorial rights: their effects are limited to the territory in which they take effect, and therefore any infringing acts are necessarily localised in that territory…
Readers will likely be aware of the cross-jurisdictional litigation considering infringement by Samsung Bioepis / Amgen’s biosimilar eculizumab products of Alexion’s patent, EP 3 167 888 B1 (“EP 888”…
It has been a little over two years since the UPC issued its first order for provisional measures on 22 June 2023. The first year saw six preliminary injunctions (PIs) granted (two ex parte) out of…
Two recent patent decisions on opposite sides of the Atlantic - EcoFactor v. Google in the United States and Optis v. Apple in the United Kingdom - highlight a growing divergence in the role of…
The legal battles surrounding osimertinib have brought significant attention to the pharmaceutical industry in Russia, particularly in relation to intellectual property rights, competition laws, and…
In a sophisticated dispute concerning methods for predicting breast cancer recurrence, the Barcelona Court of Appeal (Section 15) rejects infringement. In doing so, it holds a narrow view on method…
